LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Uždarymo kaina

28.73 -0.28

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.33

Max

28.77

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+124.82% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	17M 1.5B
Ankstesnė atidarymo kaina	29.01
Ankstesnė uždarymo kaina	28.73

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-29 23:08; UTC

Įsigijimai, susijungimai, perėmimai

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026-05-29 23:06; UTC

Įsigijimai, susijungimai, perėmimai

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026-05-29 20:53; UTC

Uždarbis

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026-05-29 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 20:33; UTC

Rinkos pokalbiai

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026-05-29 20:11; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 19:47; UTC

Uždarbis

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026-05-29 19:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026-05-29 19:22; UTC

Rinkos pokalbiai

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026-05-29 19:05; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026-05-29 18:19; UTC

Rinkos pokalbiai

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026-05-29 18:12; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026-05-29 18:11; UTC

Rinkos pokalbiai

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026-05-29 18:10; UTC

Rinkos pokalbiai

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026-05-29 17:55; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 17:55; UTC

Rinkos pokalbiai

NEAR Protocol Nearly Doubles in May -- Market Talk

2026-05-29 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026-05-29 17:00; UTC

Uždarbis

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026-05-29 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-29 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-29 16:02; UTC

Rinkos pokalbiai

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026-05-29 15:55; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-29 15:55; UTC

Rinkos pokalbiai

Cryptocurrencies Appear Detached From Stocks -- Market Talk

2026-05-29 15:50; UTC

Įsigijimai, susijungimai, perėmimai

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

2026-05-29 15:50; UTC

Įsigijimai, susijungimai, perėmimai

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

2026-05-29 15:40; UTC

Rinkos pokalbiai

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

2026-05-29 15:20; UTC

Rinkos pokalbiai

Canada's Economy Not Looking All That Bright -- Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

124.82% į viršų

12 mėnesių prognozė

Vidutinis 65.13 USD 124.82%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.